Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Knop

Showing results (121-130 of 509) with videos related to

Pageof 51
Sort By:
Frontiers in Endocrinology|January 25, 2021
Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver FatDavid S Mathiesen, Asger Lund, Tina Vilsbøll, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetesMikkel B Christensen, Salvatore Calanna, Jens J Holst, et al.
Diabetologia|June 1, 2014
Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individualsJonatan I Bagger, Filip K Knop, Asger Lund, et al.
Journal of Internal Medicine|January 6, 2016
Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemiaA E Junker, L Gluud, J J Holst, et al.
Diabetes, Obesity & Metabolism|February 9, 2018
Cardiovascular biomarkers in clinical studies of type 2 diabetesMaria P A Baldassarre, Andreas Andersen, Agostino Consoli, et al.
Diabetes, Obesity & Metabolism|March 18, 2017
Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: A reviewMartin L Kårhus, Andreas Brønden, David P Sonne, et al.
BMJ (Clinical Research Ed.)|January 13, 2012
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trialsTina Vilsbøll, Mikkel Christensen, Anders E Junker, et al.
Journal of Reproductive Immunology|August 25, 2015
Plasma YKL-40 during pregnancy and gestational diabetes mellitusAnders R Rinnov, Camilla N Rathcke, Lisbeth Bonde, et al.
Journal of Diabetes|March 21, 2019
Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription studyJakob S Knudsen, Reimar W Thomsen, Anton Pottegård, et al.
The Journal of Clinical Endocrinology and Metabolism|November 5, 2010
Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjectsKatrine B Hansen, Tina Vilsbøll, Jonatan I Bagger, et al.
Pageof 51

Showing results (121-130 of 509) with videos related to

Sort By:
Pageof 51
Frontiers in Endocrinology|January 25, 2021
Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver FatDavid S Mathiesen, Asger Lund, Tina Vilsbøll, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetesMikkel B Christensen, Salvatore Calanna, Jens J Holst, et al.
Diabetologia|June 1, 2014
Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individualsJonatan I Bagger, Filip K Knop, Asger Lund, et al.
Journal of Internal Medicine|January 6, 2016
Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemiaA E Junker, L Gluud, J J Holst, et al.
Diabetes, Obesity & Metabolism|February 9, 2018
Cardiovascular biomarkers in clinical studies of type 2 diabetesMaria P A Baldassarre, Andreas Andersen, Agostino Consoli, et al.
Diabetes, Obesity & Metabolism|March 18, 2017
Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: A reviewMartin L Kårhus, Andreas Brønden, David P Sonne, et al.
BMJ (Clinical Research Ed.)|January 13, 2012
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trialsTina Vilsbøll, Mikkel Christensen, Anders E Junker, et al.
Journal of Reproductive Immunology|August 25, 2015
Plasma YKL-40 during pregnancy and gestational diabetes mellitusAnders R Rinnov, Camilla N Rathcke, Lisbeth Bonde, et al.
Journal of Diabetes|March 21, 2019
Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription studyJakob S Knudsen, Reimar W Thomsen, Anton Pottegård, et al.
The Journal of Clinical Endocrinology and Metabolism|November 5, 2010
Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjectsKatrine B Hansen, Tina Vilsbøll, Jonatan I Bagger, et al.
Pageof 51